View Filing Data

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2015
Document And Entity Information
Entity Registrant Name	TAPIMMUNE INC
Entity Central Index Key	0001094038
Document Type	S-1
Document Period End Date	Mar. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash	$ 1,453,505	$ 141,944	$ 48,589
Prepaid expenses and deposits	82,504	82,504	15,004
Deferred financing costs			13,439
Total Current Assets	1,536,009	224,448	77,032
Current Liabilities
Accounts payable and accrued liabilities	703,323	693,362	3,778,401
Research agreement obligations	492,365	492,365	492,365
Derivative liability - conversion option			582,300
Derivative liability - warrants	2,052,975	9,415	140,504
Convertible notes payable			3,161,977
Loans payable, related party (2013 - $5,200)			42,200
Promissory notes, related party	52,942	52,942	277,942
Due to related parties			369,346
Total Current Liabilities	3,301,605	1,248,084	8,845,035
COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)
Common stock, $0.001 par value, 500,000,000 shares authorized 20,318,815 shares issued and outstanding (2013 - 1,465,712)	32,639	20,319	1,466
Additional paid-in capital	85,493,220	85,265,776	46,715,500
Accumulated deficit	(87,291,455)	(86,309,731)	(55,426,635)
Accumulated other comprehensive loss			(58,334)
Total Stockholders’ Equity (Deficit)	(1,765,596)	(1,023,636)	(8,768,003)
Total Liabilities and Stockholders’ Equity (Deficit)	1,536,009	224,448	77,032
Series B Preferred Stock [Member]
Stockholders’ Equity (Deficit)
Convertible preferred stock value
Series A Preferred Stock [Member]
Stockholders’ Equity (Deficit)
Convertible preferred stock value

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Common stock par value	$ 0.001	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000	500,000,000	500,000,000
Common stock shares issued	32,638,811	20,318,815	1,465,712
Common stock shares outstanding	32,638,811	20,318,815	1,465,712
Convertible preferred stock par value	$ 0.001	$ 0.001	$ 0.001
Convertible preferred stock authorized	10,000,000	5,000,000	5,000,000
Loans payable, related party			$ 5,200
Series B Preferred Stock [Member]
Convertible preferred stock par value	$ 0.001	$ 0.001	$ 0.001
Convertible preferred stock shares designated	1,500,000	1,500,000	1,500,000
Convertible preferred stock, issued	0	0	0
Convertible preferred stock, outstanding	0	0	0
Series A Preferred Stock [Member]
Convertible preferred stock par value	$ 0.001	$ 0.001	$ 0.001
Convertible preferred stock shares designated	1,250,000	1,250,000	1,250,000
Convertible preferred stock, issued	0	0	0
Convertible preferred stock, outstanding	0	0	0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
General and administrative	$ 418,786	$ 1,164,098	$ 3,181,927	$ 1,966,683
Research and development	609,378	22,500	189,000	697,634
Loss from Operations	(1,028,164)	(1,186,598)	(3,370,927)	(2,664,317)
Other Income (Expense)
Foreign exchange (loss) gain			(52,976)	5,896
Changes in fair value of derivative liabilities	46,440	(338,297)	581	1,546,257
Accretion of discount on convertible notes		(483,636)	(492,296)	(1,110,831)
Interest and finance charges		(35,269)	(83,247)	(645,562)
Loss on extinguishment of debt		(27,663,430)	(26,884,231)	(2,560,045)
Loss on lawsuit				(103,950)
Net Loss for the Period	(981,724)	(29,707,230)	(30,883,096)	(5,532,552)
Other comprehensive income
Foreign exchange translation adjustment		(1,249)	58,334	3,314
TOTAL COMPREHENSIVE LOSS	$ (981,724)	$ (29,708,479)	$ (30,824,762)	$ (5,529,238)
Basic and Diluted Net Loss per Share	$ (0.04)	$ (3.89)	$ (2.00)	$ (4.87)
Weighted Average Number of Common Shares Outstanding	27,611,255	7,631,669	15,465,213	1,136,115

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)	Common Stock [Member]	Additional Paid-In Capital	Retained Earnings / Accumulated Deficit	Other Comprehensive Income / Loss	Total
Balance at Dec. 31, 2012	764,029
Balance, Amount at Dec. 31, 2012	$ 782	$ 43,912,427	$ (49,894,083)	$ (61,648)
Notes converted into shares	412,047
Notes converted into shares, Amount	$ 412	1,477,175			$ 1,477,587
Stock based compensation		46,840			46,840
Obligation to issue shares at fair value pursuant to service agreements		31,891			31,891
Issued at fair value pursuant to debt settlement agreements	264,649
Issued at fair value pursuant to debt settlement agreements, Amount	265	1,211,362			1,211,627
Finders’ fee		(11,300)			(11,300)
Issued at fair value pursuant to service agreements	3,500
Issued at fair value pursuant to service agreements, Amount	$ 4	38,932			38,936
Shares issued for director compensation	2,500
Shares issued for director compensation, Amount	$ 3	8,173			8,176
Non-cash exercise of warrants	18,986
Non-cash exercise of warrants, Amount
Foreign exchange translation adjustment				3,314	3,314
Net loss			(5,532,552)		(5,532,552)
Conversion of accounts payable to common stock, Amount
Balance at Dec. 31, 2013	1,465,712
Balance, Amount at Dec. 31, 2013	$ 1,466	46,715,500	(55,426,635)	(58,334)	(8,768,003)
Shares issued for director compensation	811,000
Shares issued for director compensation, Amount	$ 811	1,390,312			1,391,123
Foreign exchange translation adjustment				58,334	58,334
Net loss			(30,883,096)		(30,883,096)
Convertible notes, promissory notes, loan payable-related party, due to related parties and accrued interest converted into Series A and B preferred stock and immediately converted into commons stock	14,048,701
Convertible notes, promissory notes, loan payable-related party, due to related parties and accrued interest converted into Series A and B preferred stock and immediately converted into commons stock, Amount	$ 14,049	30,937,029			30,951,078
Conversion of accounts payable to common stock	1,836,361
Conversion of accounts payable to common stock, Amount	$ 1,836	4,347,592			4,349,428
Private placement (net of finders’ fee)	2,157,042
Private placement (net of finders’ fee), Amount	$ 2,157	1,875,343			1,877,500
Balance at Dec. 31, 2014	20,318,816
Balance, Amount at Dec. 31, 2014	$ 20,319	85,265,776	(86,309,731)		(1,023,636)
Stock based compensation		3,750			3,750
Net loss			(981,724)		(981,724)
Private placement (net of finders’ fee)	12,319,995
Private placement (net of finders’ fee), Amount	$ 12,320	2,313,694			2,326,014
Fair value of warrants recognized as derivative liabilities		(2,090,000)			(2,090,000)
Balance at Mar. 31, 2015	32,638,811
Balance, Amount at Mar. 31, 2015	$ 32,639	$ 85,493,220	$ (87,291,455)		$ (1,765,596)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (981,724)	$ (29,707,230)	$ (30,883,096)	$ (5,532,552)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	(46,440)	338,297	(581)	(1,546,257)
Loss on extinguishment of debt		27,663,430	26,884,231	2,560,045
Accretion of discount on convertible notes			492,296	1,110,831
Non-cash interest and finance charges		483,636	83,247	645,562
Stock based compensation	3,750	690,000	1,391,123	132,093
Foreign exchange loss			58,334
Changes in operating assets and liabilities:
Prepaid expenses and deposits			(67,500)
Deferred financing costs				24,013
Accounts payable and accrued liabilities	9,961	158,913	(145,199)	1,835,315
Research agreement obligations				76,367
NET CASH USED IN OPERATING ACTIVITIES	(1,014,453)	(372,954)	(2,187,145)	(694,583)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net of issuance costs of $387,500	2,326,014		1,877,500
Convertible notes issuance		418,000	418,000	728,000
Proceeds from loans payable				32,200
Repayment to related parties				(30,867)
Repayment of convertible notes				(20,000)
Repayment of promissory notes			(15,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,326,014	418,000	2,280,500	709,333
INCREASE IN CASH	1,311,561	45,046	93,355	14,750
CASH, BEGINNING OF YEAR	141,944	48,589	48,589
CASH, END OF YEAR	1,453,505		141,944	48,589
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES
Accounts payable settled in common stock		513,000	2,415,000	558,000
Conversion of debt obligations into common stock:
Accrued interest		476,000	525,000
Convertible notes payable		3,293,000	4,116,000	738,000
Loans payable, related party		42,000	42,000
Promissory notes, related party		210,000	210,000
Due to related parties		369,000	369,000
Fair value derivative liability - conversion option at conversion		$ 708,000	$ 708,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Cash Flows [Abstract]
Net of issuance costs	$ 140,000	$ 387,500	$ 387,500

NATURE OF OPERATIONS

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

NOTE 1: NATURE OF OPERATIONS

TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

NOTE 1:NATURE OF OPERATIONS

A Phase I study at the Mayo Clinic is currently evaluating the safety and immune responses of a set of proprietary HER2/neu antigens that will be part of the "Prime" for a HER2/neu breast cancer vaccine.

A second Phase I trial is underway at Mayo Clinic (“Mayo”) in Ovarian and breast cancer (Folate Receptor Alpha). Folate Receptor Alpha is expressed in nearly 50% of breast cancers and in addition, over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence. In the USA alone, there are approximately 30,000 ovarian cancer patients newly diagnosed every year. These Folate Receptor Antigens are applicable to Ovarian and Triple Negative Breast Cancer. Both of these diseases have few treatment options if any beyond surgery and chemotherapy and therefore the Company is hopeful that it might be an ideal candidate for orphan drug status in these indications.

Phase II advancement will be assessed in the second quarter of 2015. TapImmune has an exclusive option to license this set of peptides after successful phase 1 trials.

In addition, enhancing the visibility of cancer or infected cells to a patient’s immune system is a critical aspect of an effective vaccine. In this regard, TapImmune’s PolyStart™ nucleic acid-based technology provides a four-fold increase in target cell specific naturally processed antigenic epitopes on a cells surface. This increased cell surface presentation corresponding increases activated Helper and/or long-lived Killer T-cell populations that then effectively seek out and work to destroy a patient’s cancer cells.

The Company is also exploiting the emerging field of vaccinomics for the development of vaccines applicable to a broad patient population. TapImmune's immunotherapy technologies are also aimed at the prevention of emerging viral pathogens for pandemics and biodefense.

These consolidated financial statements have been prepared on the basis of a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at December 31, 2014, the Company had a working capital deficiency and has incurred significant losses since inception in the development of its business. Further losses are anticipated raising substantial doubt as to the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on raising additional capital to fund clinical trials, ongoing research and development, maintenance and protection of patents, accommodation from certain debt obligations and ultimately on generating future profitable operations. Planned expenditures relating to current and future clinical trials of the Company’s immunotherapy vaccine will require significant additional funding. The Company is dependent on future financings to fund ongoing research and development as well as working capital requirements. The Company’s future capital requirements will depend on many factors including the rate and extent of scientific progress in its research and development programs, the timing, cost and scope involved in clinical trials, obtaining regulatory approvals, pursuing further patent protections and the timing and costs of commercialization activities.

Management is addressing going concern remediation through seeking new sources of capital, restructuring and retiring debt through conversion to equity and debt settlement arrangements with creditors, cost reduction programs and seeking possible joint venture participation. Management’s plans are intended to return the Company to financial stability and improve continuing operations. The Company is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet immediate working capital requirements.

Historically the Company has raised capital through issuances of various financial instruments and the Company recently completed significant restructuring of outstanding debt and equity instruments into equity. Additional capital is required to expand programs including pre-clinical work and to progress clinical trials for the lead vaccine candidates. Strategic partnerships will be needed to continue the product development portfolio and fund development costs. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company over the next twelve months.

There is no certainty that the Company will be able to arrange sufficient funding to satisfy current debt obligations or to continue development of products to marketability.

BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

NOTE 2: BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of March 31, 2015, condensed consolidated statements of interim financials include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2014, and notes thereto included in the Company’s annual report on Form 10-K.

LIQUIDITY AND FINANCIAL CONDITION

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

LIQUIDITY AND FINANCIAL CONDITION

NOTE 3: LIQUIDITY AND FINANCIAL CONDITION

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings.

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

As of March 31, 2015, the Company had cash and cash equivalents of approximately $1,454,000. Historically, the Company has net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 4: SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 15, 2015.

Prior Period Reclassifications

Certain prior period amounts that were combined in the March 31, 2014 consolidated financial statements have been reclassified for comparability with the March 31, 2015 presentation. These reclassifications had no effect on previously reported net loss.

NOTE 2:SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Principles of Consolidation

These financial statements include the accounts of the Company and its wholly-owned subsidiaries GeneMax Pharmaceuticals Inc. (“GPI”) and GeneMax Pharmaceuticals Canada Inc. (“GPC”). All significant intercompany balances and transactions are eliminated upon consolidation. In the fourth quarter of fiscal 2014, the Company dissolved GPC and no longer has any Canadian subsidiary.

Use of Estimates

Preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management’s estimates and assumptions include deferred taxes and related tax balances and disclosures, determining the fair value of stock-based compensation and stock based transactions, the fair value of the components of the convertible notes payable and accrued liabilities. Matters impacting the Company’s ability to continue as a going concern and contingencies also involve the use of estimates and assumptions.

Fair Value Measurements

The fair value of certain of the Company’s financial instruments, including cash and cash equivalents, accrued compensation, and other accrued liabilities, approximate cost because of their short maturities. The Company measures the fair value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:

• Level 1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.

• Level 2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

• Level 3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial Instruments and Concentration of Credit Risk.

The fair values of cash, accounts payable, and other current monetary liabilities approximate their carrying values due to the immediate or short-term maturity of these financial instruments. The Company’s operations and financing activities are conducted primarily in United States dollars, and as a result the Company is not subject to significant exposure to market risks from changes in foreign currency rates. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from assets and liabilities classified as financial instruments.

Prior Period Reclassifications

Certain prior period amounts that were combined in the December 31, 2013 consolidated financial statements have been reclassified for comparability with the December 31, 2014 presentation. These reclassifications had no effect on previously reported net loss.

Stock-Based Compensation

Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Expected Term — The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility — The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend — The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.

Deferred Financing Costs

The Company defers direct costs incurred in connection with the sale of common shares which are offset against the proceeds of the financing upon completion. Costs incurred in connection with convertible loans payable are deferred and amortized as a financing cost over the term of the convertible loans. Upon conversion of the loan, any unamortized amount of deferred financing costs will be charged to stockholders’ equity as a cost of financing.

Research and Development Costs

The Company has acquired development and marketing rights to certain technologies. The rights and licenses acquired are considered rights to unproven technology which may not have alternate future uses and therefore, have been expensed as incurred as research and development costs.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of allowances against deferred tax assets.

Derivative Liability

The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 810-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. In the event that the fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.

In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

The classification of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

In evaluating the application of ASC 815-40, management must determine whether an instrument (or an embedded feature) is indexed to the Company’s own stock. ASC 815-40-15 provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The application of ASC 815-40-15 has affected the accounting for (i) certain freestanding warrants that contain exercise price adjustment features and (ii) convertible notes containing full-ratchet and anti-dilution protections (iii) certain free standing warrants that contain contingently puttable cash settlement.

The Company has evaluated the application ASC 480-10 Distinguishing liabilities from equity, ASC 815-40 Contracts in an Entity’s Own Equity and ASC 718-10 Compensation – Stock Compensation to the issued and outstanding warrants to purchase common stock that were issued with the convertible notes, private placements, consulting agreements, and various debt settlements during 2009 through 2012. Based on the guidance, management concluded these instruments are required to be accounted for as derivatives either due to a ratchet down protection feature available on the exercise price (Note 5) or a holder’s right to put the warrants back to the Company for cash under certain conditions or a conversion option feature with conversion into variable number of shares. Under ASC 815-40-25, the Company records the fair value of these warrants and conversion options (derivatives) on its balance sheet, at fair value, with changes in the values reflected in the Statements of Operations as “Changes in fair value of derivative liabilities”. The fair value of the share purchase warrants are recorded on the Balance Sheet under ‘Derivative liability – warrants’ and the fair value of the conversion options are recorded on the Balance Sheet under ‘Derivative liability – conversion option’.

Loss per Common Share

Basic loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. If applicable, diluted earnings per share reflect the potential dilution of securities that could share in the earnings (loss) of the Company. The common shares potentially issuable on conversion of outstanding convertible debentures, warrants and stock options are anti-dilutive and have not been included in the calculation.

Net Loss per Share Applicable to Common Stockholders

Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the years ended December 31, 2014 and 2013, due to net losses.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:

	December 31,
	2014		2013
Common stock options		65,430		65,430
Common stock warrants - equity treatment		2,556,133		25,168
Common stock warrants - liability treatment		103,284		124,284
Convertible notes		-		738,760
Excluded potentially dilutive securities		2,724,847		953,642

Recently Issued Accounting Pronouncements

Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation removes all incremental financial reporting requirements for development stage entities, including the removal of reporting of the cumulative results of operations and cash flows for the period from inception to the end of the current period. The update is effective for the first annual period beginning after December 15, 2014. Early adoption is permitted, and the Company has adopted this change effective with its form 10-Q filing for the period ending September 30, 2014.

Accounting Standard Update No. ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.

POTENTIALLY DILUTIVE SECURITIES

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

POTENTIALLY DILUTIVE SECURITIES

Note 5: pOTENTIALLY DILUTIVE SECURITIES

Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the three months ended March 31, 2015 and 2014, due to net losses.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:

	March 31,
	2015		2014
Common stock options		65,000		65,000
Common stock warrants - equity treatment		52,229,000		193,000
Common stock warrants - liability treatment		12,514,000		57,000
Convertible notes		-		15,000
Potentially dilutive securities		64,808,000		330,000

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 3:ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts Payable and Accrued Liabilities

	December 31, 2014		December 31, 2013
	$		$

Trade accounts payable		620,826		1,450,083
Share-settled debt		-		1,348,663
Accrued liabilities		68,448		201,334
Employee payroll and severance		-		220,290
Accrued interest		4,088		558,032
		693,362		3,778,401

During fiscal 2014 the Company converted $2,415,000 accounts payable and accrued liabilities into 1,836,000 shares of common stock. The fair value of the shares, based on the trading price of the stock on the date of conversion, was $4,349,000 and the Company recorded a loss on extinguishment of $1,934,000.

RESEARCH AGREEMENTS

12 Months Ended

Dec. 31, 2014

Research and Development [Abstract]

RESEARCH AGREEMENTS

NOTE 4:RESEARCH AGREEMENTS

Crucell Holland B.V. (“Crucell”) – Research License and Option Agreement

Effective August 7, 2003, Crucell and the Company’s subsidiary GPI entered into a five-year research license and option agreement. In addition, retroactively effective August 7, 2008, the Company negotiated an amended license agreement for the use of Crucell’s adenovirus technology. The Company was required to make annual license payments on the anniversary of the effective date for the three year term equal to $91,000 per annum for three years through December 2011. As of December 31, 2013 and 2014, the Company accrued $492,365 under the amended agreement, inclusive of 15% interest on outstanding amounts.

The Company has not made use of the Crucell technology in its current work and has not asked for nor received any work product. Management hopes to settle the outstanding amounts with Crucell in 2015 and formally terminate the research license.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

DERIVATIVE LIABILITY

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Notes to Financial Statements

DERIVATIVE LIABILITY

NOTE 6: DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the three months ended 2015 and 2014 is as follows:

Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		0	%		0	%
Strike price	$	1.52		$	5.84
Volatility (annual)		155.00	%		159.00	%
Risk-free rate		1.37	%		0.65	%
Contractual term (years)		4.85			3.83

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants and Derivative liability – conversion option:

	As of March 31, 2015
			Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	2,053,000		-		-	$	2,053,000	$	2,053,000
Total	$	2,053,000		-		-	$	2,053,000	$	2,053,000

	As of December 31, 2014
			Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		-		-	$	9,000	$	9,000
Total	$	9,000		-		-	$	9,000	$	9,000

There were no transfers between Level 1, 2 or 3 during the three months ended March 31, 2015.

The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2015:

	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the quarter		2,090,000
Change in fair value of warrant liability		(46,000	)
Balance – March 31, 2015	$	2,053,000

The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.

During 2014 the Company entered into numerous extinguishment agreements with various holders. As a result the derivative liability associated with the bifurcated conversion options were extinguished at the date of conversion and recorded in the loss on extinguishment in the Statement of Operations. The inputs utilized in the final mark to market were as follows:

Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		-	%		0	%
Strike price	$	-		$	1.03
Volatility (annual)		-	%		199.00	%
Risk-free rate		-	%		0.05	%
Contractual term (years)		-			0.24

Fair value of Conversion Option at extinguishment	$	-		$	708,000

NOTE 5:DERIVATIVE LIABILITY

	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2014			For the Quarter ending June 30, 2014			Total
Dividend yield (per share)		0	%		0	%
Strike price	$	1.027		$	0.88
Volatility (annual)		199.00	%		199.00	%
Risk-free rate		0.05	%		0.05	%
Contractual term (years)		0.24			0.06

Fair value of Conversion Option at extinguishment	$	708,000		$	4,000		$ 712,000

December 31, 2013

December 31, 2014

Contractual

Life (Years)

Risk free Rate

Dividend yield

Volatility

Contractual

Life (Years)

Risk free Rate

Dividend yield

Volatility

Share purchase warrants

0.85 to 2.78

0.13% to 0.78%

0.00%

199%

1.22 to 3.53

0.25% to 1.10%

0.00%

155.90% to 190.68%

The foregoing assumptions are recalculated every reporting period and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

	As of December 31, 2014
			Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,415		-		-	$	9,415	$	9,415
Total	$	9,415		-		-	$	9,415	$	9,415

	As of December 31, 2013
			Fair Value Measurements
	Carrying Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	140,504		-		-	$	140,504	$	140,504
Derivative liability – conversion option		582,300		-		-		582,300		582,300
Total	$	722,804		-		-	$	722,804	$	722,804

There were no transfers between Level 1, 2 or 3 during the year ended December 31, 2014.

The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2014:

	Derivative liability – conversion option			Derivative liability – warrants
Balance – January 1, 2013	$	868,000		$	977,000
Additions during the year		811,000			206,000
Total unrealized (gains) or losses included in net loss		(1,096,000	)		-
Change in fair value of warrant liability		-			(1,043,000	)
Balance – December 31, 2013	$	583,000		$	140,000
Gain on settlement of debt		(714,000	)		-
Change in fair value of conversion option liability		131,000			-
Change in fair value of warrant liability		-			(131,000	)
Balance – December 31, 2014	$	-		$	9,000

The net cash settlement value at the time of any future transactions, where the Company consolidates or merges with another entity, will depend upon the value of the following inputs at that time: the consideration value per share of the Company’s common stock, the volatility of the Company’s common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based on U.S. Treasury security yields, and the Company’s dividend yield. The warrant requires use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day immediately following announcement of a Fundamental Transaction.

CONVERTIBLE NOTES PAYABLE

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

CONVERTIBLE NOTES PAYABLE

NOTE 6:CONVERTIBLE NOTES PAYABLE

The following table summarizes the Company’s outstanding convertible note obligations:

		Stated				Principal Balance Outstanding
Issue Date	Maturity Date	Interest Rate			Conversion Terms	December 31, 2014		December 31, 2013
2/24/2011	2/24/2014		10.0	%	Variable at $25.00		$ -		$ 980,858
4/4/2011	4/4/2014		10.0	%	Variable at $25.00		-		215,000
6/6/2011	6/6/2014		10.0	%	Variable at $25.00		-		30,000
8/12/2012	11/12/2012		10.0	%	Variable at $9.00		-		27,500
8/20/2012	8/20/2013		8.0	%	Variable at $9.00		-		20,000
10/15/2012	10/15/2013		8.0	%	Variable at $12.00		-		340,000
11/20/2012	11/20/2013		5.0	%	Variable at $9.00		-		10,748
12/18/2012	12/14/2013		9.0	%	Fixed at $10.00		-		50,000
1/5/2013	5/31/2014		None		Fixed at $8.00		-		452,729
1/31/2013	5/31/2014		None		Fixed at $4.00		-		24,135
2/27/2013	2/27/2014		5.0	%	Variable at $9.00		-		58,500
4/2/2013	6/2/2013		8.0	%	Fixed at $7.00		-		80,967
4/18/2013	12/18/2013		8.0	%	Fixed at $7.00		-		31,688
5/2/2013	5/31/2014		10.0	%	Variable at $3.44		-		50,000
5/5/2013	7/5/2013		8.0	%	Fixed at $7.00		-		45,000
5/14/2013	5/14/2014		8.0	%	Fixed at $6.00		-		126,000
6/27/2013	6/27/2014		5.0	%	Variable at $9.00		-		37,620
6/19/2013	6/19/2014		10.0	%	Variable at $9.00		-		32,000
7/12/2013	7/12/2014		8.0	%	Fixed at $3.00		-		96,800
10/18/2013	4/18/2014		None		Variable at $1.00		-		94,444
11/1/2013	5/1/2014		None		Variable at $1.00		-		80,000
12/19/2013	6/19/2014		None		Variable at $1.00		-		277,222
12/23/2013	6/23/2014		10.0	%	Fixed at $7.00		-		536,400

	Total convertible notes					$	-	$	3,697,611
	Unamortized note discount						-		(535,634)
	Total on Balance sheet					$	-	$	3,161,977

Issuance of Convertible Preferred Stock

During the year the Company issued $418,000 of convertible notes. The notes carried no interest rate and were converted shortly thereafter (see Extinguishment loss) into preferred stock and immediately into common stock.

Debt converted to Preferred Stock and immediately converted into common stock

During the year, note holders that included Convertible notes, Loans payable, Promissory notes-related party & Due to related party exchanged approximately $4.7 million of debt and $0.5 million of accrued interest for shares of preferred stock, which was immediately converted into 14.0 million shares of common stock with a fair value of approximately $31 million. The total loss on extinguishment associated with the note conversions was $24.9 million, which includes the extinguishment of the derivative liability – conversion option of $0.7 million.

LOANS PAYABLE

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

LOANS PAYABLE

NOTE 7:LOANS PAYABLE

As at December 31, 2014, there were unsecured loan payable in the amount of $nil (December 31, 2013 - $42,200). During the year ended December 31, 2014, investors converted $37,000 and a related party converted $5,200 of the loan into preferred stock which was immediately converted into common stock (see note 6).

PROMISSORY NOTES, RELATED PARTY

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Equity [Abstract]

PROMISSORY NOTES, RELATED PARTY

NOTE 7: PROMISSORY NOTES, RELATED PARTY

The Company has outstanding promissory notes in the amount of $52,942 (December 31, 2014 - $52,942), of which $23,000 of promissory notes are from an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment terms.

NOTE 8:PROMISSORY NOTES, RELATED PARTY

The Company has outstanding promissory notes in the amount of $52,942 (December 31, 2013 - $277,942), of which $23,000 of promissory notes are from an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment terms.

During the year ended December 31, 2014, a note holder converted outstanding principal of $210,000 and accrued interest of $12,000 into preferred stock which was immediately converted into common shares (see note 6).

During the year ended December 31, 2014, $15,000 (2013 - $nil) of the promissory notes were repaid to an officer and director of the Company.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

DUE TO RELATED PARTIES

12 Months Ended

Dec. 31, 2014

DUE TO RELATED PARTIES

NOTE 9:DUE TO RELATED PARTIES

During the year ended December 31, 2014 the Company has outstanding promissory notes in the amount of $nil (December 31, 2013 - $369,000). During the fiscal year 2014, the related parties converted the notes of $369,000 into preferred stock which was immediately converted into common stock (See note 6).

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

CAPITAL STOCK

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Equity [Abstract]

CAPITAL STOCK

NOTE 8: CAPITAL STOCK

2015 Share Transactions

Private placements

In January, 2015, the Company entered into a Securities Purchase Agreement with certain investors for the sale of 7,320,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “January 2015 Warrants”). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B warrants are exercisable at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with a five year term. Series D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are exercised, with a five year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25 per share, only if and to the extent that the Series C warrants are exercised, with a five year term from the date that the Series C warrants are exercised.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 366,000 common shares with substantially the same terms as the January 2015 Warrants.

The Series A warrants were issued with price reset features. The fair value of these warrants was determined to be $1,346,000 and recognized as a derivative liability.

The fair value of Series B, C, D & E warrants was determined to be $4,635,000 and was included within equity.

In March, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 5,000,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 125,000 common shares with substantially the same terms as the March 2015 Warrants.

The Series A warrants were issued with price reset features. The fair value of these warrants was determined to be $744,000 and recognized as a derivative liability.

The fair value of Series B, C, D & E warrants was determined to be $2,588,000 and was included within equity.

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of March 31, 2015 and changes during the period is presented below:

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life

Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		62,090,975			1.03		3.96
Exercised		-			-		-
Extinguished or expired		(7,500	)		50.00		-
Balance, March 31, 2015		64,742,892		$	1.01		3.95

NOTE 10: CAPITAL STOCK

Stock Split and increase in authorized shares

On February 18, 2014, the Company completed a reverse stock split thereby issuing 1 new share for each 100 outstanding shares of the Company’s common stock and amended the Company’s Articles of Incorporation to increase the authorized shares of common stock from 150,000,000 shares of common stock to 500,000,000 shares.

Share Capital

On January 6, 2014, the Company designated 1,250,000 Series A preferred shares par value $0.001 (“Series A Convertible Preferred Stock”). Each share of Series A Convertible Preferred Stock automatically converted into five (5) shares of the Company’s common stock upon the occurrence of the 1:100 reverse stock split.

On February 18, 2014, the Company created a class of up to 1,500,000 preferred shares, par value $0.001, called Series B convertible preferred stock (“Series B Convertible Preferred Stock”). The terms of the Series B Convertible Preferred Stock are:

rank pari passu to the common stock with respect to rights on liquidation, winding up and dissolution;

have no dividend rights except as may be declared by the Board in its sole and absolute discretion;

shall have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote of holders of the Corporation’s common stock; and

shall automatically convert into seven (7) shares of common upon the occurrence of a 1:100 reverse stock split.

All prior period share transactions included in the Company’s stock transactions and balances have been retroactively restated for the reverse stock splits described above. There are no shares outstanding under preferred shares as of December 31, 2014.

2014 Share Transactions

Consulting services

During the year ended December 31, 2014, the Company issued in aggregate 811,000 shares of common stock in exchange for consulting services for which performance was complete. The fair value of the common stock recognized was approximately $954,000.

Private placements

During the year ended December 31, 2014, the Company entered into a Securities Purchase Agreement with a single institutional investor for the sale of 1,886,792 units at a purchase price of $1.06 per unit, for a total purchase price of $1,836,000, net of finders’ fee of $164,000. Each unit consists of one common share and one share purchase warrant exercisable at $1.17 for a period of 5 years. The Company also issued 94,340 placement agent share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $1.325 per share for an exercise period of up to five years from the issuance date. The warrants were included within equity. The fair value of these warrants was determined to be $111,000, using the Black-Scholes Option Pricing Model with a contractual term of 5 years, a risk free interest rate of 1.66%, a dividend yield of 0%, and an expected volatility of 150.3%.

During the year ended December 31, 2014, the Company received subscription proceeds of $265,000 for 265,000 units. Each unit consists of one share of common stock and one share purchase warrant exercisable at $2.50 for a period of 3 years. The Company also issued 5,250 shares of common stock as finders’ fee relating to the subscription proceeds. The fair value of the common stock was determined to be $5,250.

Stock Compensation Plan

On October 14, 2009, the Company adopted the 2009 Stock Incentive Plan (the “2009 Plan”) which supersedes and replaces the 2007 Stock Plan. The 2009 Plan allows for the issuance of up to 100,000 common shares. Options granted under the Plan shall be at prices and for terms as determined by the Board of Directors.

The expensed portion of the value of the granted and vested options during the year ended December 31, 2014 was $15,000 (2013 - $132,093) which was recorded as stock based consulting and management fees.

Share purchase options

A summary of the Company’s stock options as of December 31, 2014 and 2013 and changes during the years is presented below:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life

Balance, December 31, 2012		65,430		18.00		6.05
Issued		-		-		-
Cancelled/Forfeited		-		-		-

Balance, December 31, 2013		65,430		18.00		5.04
Issued		-		-		-
Cancelled/Forfeited		-		-		-
Balance, December 31, 2014		65,430	$	18.00		4.04

At December 31, 2014, the intrinsic value of the vested options was equal to $nil (2013 - $nil).

A summary of the status of the Company’s unvested options as of December 31, 2014 is presented below:

	Number of Shares			Weighted Average Grant-Date Fair Value

Unvested, December 31, 2013		1,111		$	18.00
Granted		-			-
Vested		(833	)		18.00
Cancelled		-			-

Unvested, December 31, 2014		278		$	18.00

Share Purchase Warrants

In September, 2014, the Company issued 100,000 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $1.15 per share for an exercise period of up to five years from the issuance date. The warrants were issued pursuant to a service agreement. The fair value of these warrants was determined to be $105,000, using the Black-Scholes Option Pricing Model with a contractual term of 5 years, a risk free interest rate of 1.63%, a dividend yield of 0%, and an annual volatility of 150.18%.

In March, 2014, the Company issued 100,000 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $4.00 per share for an exercise period of up to four years from the issuance date. The warrants were issued pursuant to a technology option agreement. The fair value of these warrants was determined to be $303,000 and was recorded in general and administrative expenses. The weighted average assumptions used for the Black-Scholes option-pricing model to value these warrants were: volatility of 156.6%, risk free rate of 1.4%, term of 4 years and dividend rate of 0%. The Company used the Black-Scholes option-pricing model as the resultant fair value is not significantly different than the Monte Carlo option pricing model. In August 2014, the Company repriced the 100,000 warrants by reducing the exercise price from $4.00 to $1.06. As a result, the Company recorded incremental fair value of $14,000 during the year ended December 31, 2014.

A summary of the Company’s share purchase warrants as of December 31, 2014 and changes during the year is presented below:

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life

Balance, December 31, 2013		149,452			25.85		2.76
Issued		2,546,132			1.30		4.23
Exercised		-			-		-
Extinguished or expired		(36,167	)		40.00		-
Balance, December 31, 2014		2,659,417		$	1.83		4.15

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

INCOME TAXES

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 11: INCOME TAXES

The income tax provision (benefit) for the years ended December 31, 2014 and 2013 are as follows:

	Year Ended			Year Ended
	December 31, 2014			December 31, 2013


Federal:
Current	$	-		$	-
Deferred		(1,265,000	)		(1,321,000	)

State:
Current		-			-
Deferred		-			-
		(1,265,000	)		(1,321,000	)
Change in valuation allowance		1,265,000			1,321,000
Income tax provision (benefit)	$	-		$	-

The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2014 and 2013 are as follows:

	Year Ended			Year Ended
	December 31, 2014			December 31, 2013

Deferred tax assets:
Ney operating loss carryforwards	$	10,433,000		$	9,174,000
Stock-based compensation	$	1,871,000		$	1,866,000
Technology licensing fee		167,000			167,000
Total deferred tax assets		12,471,000			11,207,000
Valuation allowance		(12,471,000	)		(11,207,000	)
Deferred tax assets, net of valuation allowance	$	-		$	-

The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2014 and 2013.

The Company has not filed U.S tax returns since inception, but is in the process of filing tax returns for the years ended December 31, 2014, 2013, 2012, 2011, 2010, and 2009. The Net operating losses (“NOLs”) will not be available to reduce future taxable income until the returns are filed. Assuming these returns are filed, as of December 31, 2014 and 2013, the Company has approximately $30,686,428 and $26,982,085, respectively, of federal NOLs that may be available to offset future taxable income, if any. The federal net operating loss carryforwards, if not utilized, will expire beginning in 2023.

The Company has also not filed any Canadian tax returns for GPC, which was dissolved in the fourth quarter of fiscal year 2014. The Company could be subject to fines and penalties for not filing the tax returns. The Company does not know the quantum of such fines and penalties, if any, and no liabilities have been accrued in the fiscal year 2014.

In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section 382 analysis has not been prepared and NOLs could be subject to limitation under Section 382.

For the years ended December 31, 2014 and 2013, the expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

	Year Ended			Year Ended
	December 31, 2014			December 31, 2013

U.S. federal statutory rate	$	(10,449,000	)	$	(1,881,000	)

Permanent differences
- Non-cash loss on extinguishment of debt		9,122,000			893,000
-Other permanent differences		62,000			(334,000	)
Change in valuation allowance		1,265,000			1,322,000
Income tax provision (benefit)	$	-		$	-

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2014 and 2013, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2014 and 2013. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.

CONTINGENCIES AND COMMITMENTS

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

CONTINGENCIES AND COMMITMENTS

NOTE 9: CONTINGENCIES AND COMMITMENTS

Contingencies:

Consultant Litigation

In May 2012, the Company issued 112,000 post-consolidated shares of common stock to two consultants. The Company contested the validity of the services provided and initially was able to delay the sale of the contested shares. The Company was not successful in recovering the contested shares. A claim for alleged damages of approximately $362,000 plus costs by one of the consultants as a result of the contesting of the issuance of the shares was filed in the Supreme Court of New York. The claim was for damages on the difference between market price at the time the Company was able to delay the sale of his shares and the market price at the time of the sale of all of his shares. As the result of a judicial decision in New York the consultant received a bond payment of approximately $100,000 that the Company had used to secure a temporary restraining order against the issuance of stock to him. Following hearings at the International Arbitration Tribunal held in New York on May 13-16, 2014 the arbitrator ordered (on July 18, 2014) the consultant to pay TapImmune $196,204 plus 9% interest from the date of the award. The Company is attempting to collect the award from Mr. Michael Gardner.

On July 18, 2014, the International Center for Dispute Resolution International Arbitration Tribunal issued a Final Award in the matter of TapImmune Inc. vs. Michael Gardner awarding TapImmune $196,204 plus post-award interest at a rate of 9% per year. This award stemmed from the dispute discussed above with Mr. Gardner regarding the May 2012 consulting agreement. The arbitrator found that we were fraudulently induced into entering said agreement through “1) misrepresentations as to what he would or could do for the Company, including raising funds, and 2) omissions about his reputation and ability to obtain or assist in obtaining financing for TapImmune” among other reasons. We are attempting to collect the award from Mr. Gardner.

Vendor Litigation

One of our suppliers, Fischer Scientific was awarded a judgment against us for $51,000 which is equal to the amount owed to them and is currently accrued on the balance sheet. We intend on settling that matter in the second quarter of 2015.

NOTE 12:CONTINGENCIES AND COMMITMENTS

Contingencies:

Consultant Litigation

In May 2012, the Company issued 112,000 post-consolidated shares of common stock to two consultants. The Company contested the validity of the services provided and initially were able to delay the sale of the contested shares. The Company was not successful in recovering the contested shares. A claim for alleged damages of approximately $362,000 plus costs by one of the consultants as a result of the contesting of the issuance of the shares has been filed in the Supreme Court of New York. The claim is for damages on the difference between market price at the time the Company was able to delay the sale of his shares and the market price at the time of the sale of all of his shares. As the result of a judicial decision in New York the consultant received a bond payment of approximately $100,000 that the Company had used to secure a temporary restraining order against the issuance of stock to him. Following hearings at the International Arbitration Tribunal held in New York on May 13-16 the arbitrator ordered (on July 18, 2014) the consultant to pay TapImmune $196,204 plus 9% interest from the date of the award. The Company is attempting to collect the award from Mr. Gardner.

The law firm that we used to pursue the Gardner Action was awarded a judgment against us for $210,255 of unpaid legal fees (“G&S Judgment”). Shareholders of the Company acquired the G&S Judgment in full, converted that Judgment into preferred shares of the Company (which in turn converted into common stock) and subsequently released the Company from any liability related thereto.

One of our suppliers, Fischer Scientific was awarded a judgment against us for $51,000 which is equal to the amount owed to them. We intend on settling that matter in the second quarter of 2015.

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 13:SUBSEQUENT EVENTS

On January 12, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 7,320,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants collectively, the “January 2015 Warrants”). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B warrants are exercisable at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with a five year term. Series D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are exercised, with a five year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25 per share, only if and to the extent that the Series C warrants are exercised, with a five year term from the date that the Series C warrants are exercised.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase an aggregate of up to 5% of the aggregate number of shares of common stock sold in the offering to the placement agents. The placement agent warrants have substantially the same terms as the January 2015 Warrants.

On March 9, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 5,000,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants collectively, the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase an aggregate of up to 2.5% of the aggregate number of shares of common stock sold in the offering to the placement agents. The placement agent warrants have substantially the same terms as the March 2015 Warrants.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Principles of Consolidation

Use of Estimates

Fair Value Measurements

• Level 1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.

Prior Period Reclassifications

Prior Period Reclassifications

Prior Period Reclassifications

Stock-Based Compensation

Expected Volatility — The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

Deferred Financing Costs

Research and Development Costs

Income Taxes

Derivative Liability

Loss per Common Share

Net Loss per Share Applicable to Common Stockholders

Net Loss per Share Applicable to Common Stockholders

Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the years ended December 31, 2014 and 2013, due to net losses.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:

	December 31,
	2014		2013
Common stock options		65,430		65,430
Common stock warrants - equity treatment		2,556,133		25,168
Common stock warrants - liability treatment		103,284		124,284
Convertible notes		-		738,760
Excluded potentially dilutive securities		2,724,847		953,642

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Summary of securities were not included in the diluted net loss per share calculation

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:

	December 31,
	2014		2013
Common stock options		65,430		65,430
Common stock warrants - equity treatment		2,556,133		25,168
Common stock warrants - liability treatment		103,284		124,284
Convertible notes		-		738,760
Excluded potentially dilutive securities		2,724,847		953,642

POTENTIALLY DILUTIVE SECURITIES (Table)

3 Months Ended

Mar. 31, 2015

Notes to Financial Statements

POTENTIALLY DILUTIVE SECURITIES

	March 31,
	2015		2014
Common stock options		65,000		65,000
Common stock warrants - equity treatment		52,229,000		193,000
Common stock warrants - liability treatment		12,514,000		57,000
Convertible notes		-		15,000
Potentially dilutive securities		64,808,000		330,000

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities

	December 31, 2014	December 31, 2013
	$	$

Trade accounts payable	620,826	1,450,083
Share-settled debt	-	1,348,663
Accrued liabilities	68,448	201,334
Employee payroll and severance	-	220,290
Accrued interest	4,088	558,032
	693,362	3,778,401

DERIVATIVE LIABILITY (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Notes to Financial Statements

Summary of inputs utilized in the final mark to market

The inputs utilized in the final mark to market were as follows:

Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		-	%		0	%
Strike price	$	-		$	1.03
Volatility (annual)		-	%		199.00	%
Risk-free rate		-	%		0.05	%
Contractual term (years)		-			0.24

Fair value of Conversion Option at extinguishment	$	-		$	708,000

The inputs utilized in the final mark to market were as follows:

	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2014			For the Quarter ending June 30, 2014			Total
Dividend yield (per share)		0	%		0	%
Strike price	$	1.027		$	0.88
Volatility (annual)		199.00	%		199.00	%
Risk-free rate		0.05	%		0.05	%
Contractual term (years)		0.24			0.06

Fair value of Conversion Option at extinguishment	$	708,000		$	4,000		$ 712,000

Summary of share purchase warrants

December 31, 2013

December 31, 2014

Contractual

Life (Years)

Risk free Rate

Dividend yield

Volatility

Contractual

Life (Years)

Risk free Rate

Dividend yield

Volatility

Share purchase warrants

0.85 to 2.78

0.13% to 0.78%

0.00%

199%

1.22 to 3.53

0.25% to 1.10%

0.00%

155.90% to 190.68%

Summary ofderivative liability - warrants and Derivative liability - conversion option

	As of March 31, 2015
			Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	2,053,000		-		-	$	2,053,000	$	2,053,000
Total	$	2,053,000		-		-	$	2,053,000	$	2,053,000

	As of December 31, 2014
			Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		-		-	$	9,000	$	9,000
Total	$	9,000		-		-	$	9,000	$	9,000

	As of December 31, 2014
		Fair Value Measurements
	Fair Value	Level 1	Level 2	Level 3	Total
Derivative liability - warrants	$ 9,415	-	-	$ 9,415	$ 9,415
Total	$ 9,415	-	-	$ 9,415	$ 9,415

	As of December 31, 2013
		Fair Value Measurements
	Carrying Value	Level 1	Level 2	Level 3	Total
Derivative liability - warrants	$ 140,504	-	-	$ 140,504	$ 140,504
Derivative liability – conversion option	582,300	-	-	582,300	582,300
Total	$ 722,804	-	-	$ 722,804	$ 722,804

Summary of changes in Level 3 liabilities measured at fair value

The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2015:

	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the quarter		2,090,000
Change in fair value of warrant liability		(46,000	)
Balance – March 31, 2015	$	2,053,000

The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2014:

	Derivative liability – conversion option	Derivative liability – warrants
Balance – January 1, 2013	$868,000	$977,000
Additions during the year	811,000	206,000
Total unrealized (gains) or losses included in net loss	(1,096,000)	-
Change in fair value of warrant liability	-	(1,043,000)
Balance – December 31, 2013	$583,000	$140,000
Gain on settlement of debt	(714,000)	-
Change in fair value of conversion option liability	131,000	-
Change in fair value of warrant liability	-	(131,000)
Balance – December 31, 2014	$ -	$ 9,000

Summary of valuation methodology

Share Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending March 31, 2015			For the Quarter Ending March 31, 2014
Dividend yield (per share)		0	%		0	%
Strike price	$	1.52		$	5.84
Volatility (annual)		155.00	%		159.00	%
Risk-free rate		1.37	%		0.65	%
Contractual term (years)		4.85			3.83

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

CONVERTIBLE NOTES PAYABLE (Tables)

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Debt instrument transactions

The following table summarizes the Company’s outstanding convertible note obligations:

		Stated				Principal Balance Outstanding
Issue Date	Maturity Date	Interest Rate			Conversion Terms	December 31, 2014		December 31, 2013
2/24/2011	2/24/2014		10.0	%	Variable at $25.00		$ -		$ 980,858
4/4/2011	4/4/2014		10.0	%	Variable at $25.00		-		215,000
6/6/2011	6/6/2014		10.0	%	Variable at $25.00		-		30,000
8/12/2012	11/12/2012		10.0	%	Variable at $9.00		-		27,500
8/20/2012	8/20/2013		8.0	%	Variable at $9.00		-		20,000
10/15/2012	10/15/2013		8.0	%	Variable at $12.00		-		340,000
11/20/2012	11/20/2013		5.0	%	Variable at $9.00		-		10,748
12/18/2012	12/14/2013		9.0	%	Fixed at $10.00		-		50,000
1/5/2013	5/31/2014		None		Fixed at $8.00		-		452,729
1/31/2013	5/31/2014		None		Fixed at $4.00		-		24,135
2/27/2013	2/27/2014		5.0	%	Variable at $9.00		-		58,500
4/2/2013	6/2/2013		8.0	%	Fixed at $7.00		-		80,967
4/18/2013	12/18/2013		8.0	%	Fixed at $7.00		-		31,688
5/2/2013	5/31/2014		10.0	%	Variable at $3.44		-		50,000
5/5/2013	7/5/2013		8.0	%	Fixed at $7.00		-		45,000
5/14/2013	5/14/2014		8.0	%	Fixed at $6.00		-		126,000
6/27/2013	6/27/2014		5.0	%	Variable at $9.00		-		37,620
6/19/2013	6/19/2014		10.0	%	Variable at $9.00		-		32,000
7/12/2013	7/12/2014		8.0	%	Fixed at $3.00		-		96,800
10/18/2013	4/18/2014		None		Variable at $1.00		-		94,444
11/1/2013	5/1/2014		None		Variable at $1.00		-		80,000
12/19/2013	6/19/2014		None		Variable at $1.00		-		277,222
12/23/2013	6/23/2014		10.0	%	Fixed at $7.00		-		536,400

	Total convertible notes					$	-	$	3,697,611
	Unamortized note discount						-		(535,634)
	Total on Balance sheet					$	-	$	3,161,977

CAPITAL STOCK (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Equity [Abstract]

Summary of share purchase options

A summary of the Company’s stock options as of December 31, 2014 and 2013 and changes during the years is presented below:

	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Life

Balance, December 31, 2012	65,430	18.00	6.05
Issued	-	-	-
Cancelled/Forfeited	-	-	-

Balance, December 31, 2013	65,430	18.00	5.04
Issued	-	-	-
Cancelled/Forfeited	-	-	-
Balance, December 31, 2014	65,430	$ 18.00	4.04

A status summary of unvested options

A summary of the status of the Company’s unvested options as of December 31, 2014 is presented below:

	Number of Shares	Weighted Average Grant-Date Fair Value

Unvested, December 31, 2013	1,111	$ 18.00
Granted	-	-
Vested	(833)	18.00
Cancelled	-	-

Unvested, December 31, 2014	278	$ 18.00

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of March 31, 2015 and changes during the period is presented below:

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life

Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		62,090,975			1.03		3.96
Exercised		-			-		-
Extinguished or expired		(7,500	)		50.00		-
Balance, March 31, 2015		64,742,892		$	1.01		3.95

A summary of the Company’s share purchase warrants as of December 31, 2014 and changes during the year is presented below:

	Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Life

Balance, December 31, 2013	149,452	25.85	2.76
Issued	2,546,132	1.30	4.23
Exercised	-	-	-
Extinguished or expired	(36,167)	40.00	-
Balance, December 31, 2014	2,659,417	$ 1.83	4.15

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2014

Supplemental Cash Flow Elements [Abstract]

Summary of income tax provision (benefit)

The income tax provision (benefit) for the years ended December 31, 2014 and 2013 are as follows:

	Year Ended	Year Ended
	December 31, 2014	December 31, 2013


Federal:
Current	$ -	$ -
Deferred	(1,265,000)	(1,321,000)

State:
Current	-	-
Deferred	-	-
	(1,265,000)	(1,321,000)
Change in valuation allowance	1,265,000	1,321,000
Income tax provision (benefit)	$ -	$ -

Summary of effects of temporary differences that give rise to significant portions of the deferred tax assets

The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2014 and 2013 are as follows:

	Year Ended	Year Ended
	December 31, 2014	December 31, 2013

Deferred tax assets:
Ney operating loss carryforwards	$ 10,433,000	$ 9,174,000
Stock-based compensation	$ 1,871,000	$ 1,866,000
Technology licensing fee	167,000	167,000
Total deferred tax assets	12,471,000	11,207,000
Valuation allowance	(12,471,000)	(11,207,000)
Deferred tax assets, net of valuation allowance	$ -	$ -

Summary of expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with the actual tax provision (benefit)

For the years ended December 31, 2014 and 2013, the expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

	Year Ended	Year Ended
	December 31, 2014	December 31, 2013

U.S. federal statutory rate	$ (10,449,000)	$ (1,881,000)

Permanent differences
- Non-cash loss on extinguishment of debt	9,122,000	893,000
-Other permanent differences	62,000	(334,000)
Change in valuation allowance	1,265,000	1,322,000
Income tax provision (benefit)	$ -	$ -

NATURE OF OPERATIONS (Details Narrative)	12 Months Ended
NATURE OF OPERATIONS (Details Narrative)	Dec. 31, 2014 Patients / Number
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of ovarian cancer patients	30,000
Percentage of breast cancers	50.00%
Percentage ofof ovarian cancers	95.00%

LIQUIDITY AND FINANCIAL CONDITION (Details Narrtive)	Mar. 31, 2015 USD ($)
Liquidity And Financial Condition Details Narrtive
Cash and cash equivalents	$ 1,454,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Common stock options	65,000	65,000	65,430	65,430
Common stock warrants - equity treatment	52,229,000	193,000	2,556,133	25,168
Common stock warrants - liability treatment	12,514,000	57,000	103,284	124,284
Convertible notes		15,000		738,760
Excluded potentially dilutive securities	64,808,000	330,000	2,724,847	953,642

POTENTIALLY DILUTIVE SECURITIES (Details) - shares	3 Months Ended		12 Months Ended
POTENTIALLY DILUTIVE SECURITIES (Details) - shares	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Potentially Dilutive Securities Details
Common stock options	65,000	65,000	65,430	65,430
Common stock warrants - equity treatment	52,229,000	193,000	2,556,133	25,168
Common stock warrants - liability treatment	12,514,000	57,000	103,284	124,284
Convertible notes		15,000		738,760
Potentially dilutive securities	64,808,000	330,000	2,724,847	953,642

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Trade accounts payable	$ 620,826	$ 1,450,083
Share-settled debt		1,348,663
Accrued liabilities	68,448	201,334
Employee payroll and severance		220,290
Accrued interest	4,088	558,032
Total accounts Payable and Accrued Liabilities	$ 693,362	$ 3,778,401

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)	12 Months Ended
	Dec. 31, 2014 USD ($) shares
Payables and Accruals [Abstract]
Accounts payable and accrued liabilities	$ 2,415,000
Common stock, Shares issued \| shares	1,836,000
Trading of shares at fair value	$ 4,349,000
Loss on extinguishment	$ 1,934,000

RESEARCH AGREEMENTS (Details Narrative)	12 Months Ended
RESEARCH AGREEMENTS (Details Narrative)	Dec. 31, 2014 USD ($)
Research and Development [Abstract]
Annual license payments	$ 91,000
Accrued liablities	$ 492,365
Interest rate on outstanding amounts	15.00%

DERIVATIVE LIABILITY (Details) - USD ($)	3 Months Ended			12 Months Ended
DERIVATIVE LIABILITY (Details) - USD ($)	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014
Notes to Financial Statements
Dividend yield (per share)		0.00%	0.00%
Strike price		$ 0.88	$ 1.027
Volatility (annual)		199.00%	199.00%
Risk-free rate		0.05%	0.05%
Contractual term (years)		22 days	2 months 27 days
Fair value of Conversion Option at extinguishment		$ 4,000	$ 708,000	$ 712,000

DERIVATIVE LIABILITY (Details 1) - Share Purchase Warrants[Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 30, 2013
Contractual Life (Years)	4 years 10 months 6 days	3 years 9 months 29 days
Risk free Rate	1.37%	0.65%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	155.00%	159.00%		199.00%
Maximum [Member]
Contractual Life (Years)			3 years 6 months 11 days		2 years 9 months 11 days
Risk free Rate			1.10%		0.78%
Volatility			19068.00%
Minimum [Member]
Contractual Life (Years)			1 year 2 months 19 days	10 months 6 days
Risk free Rate			0.25%	0.13%
Volatility			155.90%

DERIVATIVE LIABILITY (Details 2) - USD ($)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Derivative liability - warrants	$ 2,053,000	$ 9,000	$ 140,504
Derivative liability - conversion option			582,300
Total	2,053,000	9,000	722,804
Fair Value, Inputs, Level 2 [Member]
Derivative liability - warrants
Derivative liability - conversion option
Total
Fair Value [Member]
Derivative liability - warrants	2,053,000	9,000
Total	2,053,000	9,000
Fair Value, Inputs, Level 1 [Member]
Derivative liability - warrants
Derivative liability - conversion option
Total
Fair Value, Inputs, Level 3 [Member]
Derivative liability - warrants	2,053,000	9,000	140,504
Derivative liability - conversion option			582,300
Total	$ 2,053,000	$ 9,000	722,804
Carrying Value [Member]
Derivative liability - warrants			140,504
Derivative liability - conversion option			582,300
Total			$ 722,804

DERIVATIVE LIABILITY (Details 3) - USD ($)	3 Months Ended	12 Months Ended
DERIVATIVE LIABILITY (Details 3) - USD ($)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Balance - December 31, 2013	$ 9,000
Additions during the year	2,090,000
Change in fair value of warrant liability	(46,000)
Balance - December 31, 2014	$ 2,053,000
ConversionOption[Member]
Balance - December 31, 2013		$ 583,000	$ 868,000
Additions during the year			811,000
Total unrealized (gains) or losses included in net loss			(1,096,000)
Loss on settlement of debt		(714,000)
Change in fair value of conversion option liability		131,000
Change in fair value of warrant liability
Balance - December 31, 2014			583,000
SharePurchaseWarrants[Member]
Balance - December 31, 2013		140,000	977,000
Additions during the year			206,000
Total unrealized (gains) or losses included in net loss
Loss on settlement of debt
Change in fair value of conversion option liability
Change in fair value of warrant liability		(131,000)	(1,043,000)
Balance - December 31, 2014		$ 9,000	$ 140,000

DERIVATIVE LIABILITY (Details 4) - $ / shares	3 Months Ended			12 Months Ended
DERIVATIVE LIABILITY (Details 4) - $ / shares	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 30, 2013
Strike price		$ 0.88	$ 1.027
Share Purchase Warrants[Member]
Dividend yield (per share)	0.00%		0.00%	0.00%	0.00%
Strike price	$ 1.52		$ 5.84
Volatility (annual)	155.00%		159.00%		199.00%
Risk free Rate	1.37%		0.65%
Contractual term (years)	4 years 10 months 6 days		3 years 9 months 29 days
Maximum [Member] \| Share Purchase Warrants[Member]
Volatility (annual)				19068.00%
Risk free Rate				1.10%		0.78%
Contractual term (years)				3 years 6 months 11 days		2 years 9 months 11 days
Minimum [Member] \| Share Purchase Warrants[Member]
Volatility (annual)				155.90%
Risk free Rate				0.25%	0.13%
Contractual term (years)				1 year 2 months 19 days	10 months 6 days

CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	12 Months Ended
CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Total convertible notes		$ 3,697,611
Unamortized note discount		(535,634)
Total on Balance sheet		3,161,977
Convertible Notes Payable 22 [Member]
Issue Date	--12-23
Maturity Date	--06-23
Stated Interest Rate	10.00%
Conversion Terms	Fixed at $7.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		536,400
Convertible note [Member]
Issue Date	--02-24
Maturity Date	--02-24
Stated Interest Rate	10.00%
Conversion Terms	Variable at $25.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		980,858
Convertible Note1 [Member]
Issue Date	--04-04
Maturity Date	--04-04
Stated Interest Rate	10.00%
Conversion Terms	Variable at $25.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		215,000
Convertible Note2 [Member]
Issue Date	--06-06
Maturity Date	--06-06
Stated Interest Rate	10.00%
Conversion Terms	Variable at $25.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		30,000
Convertible Note3 [Member]
Issue Date	--08-12
Maturity Date	--11-12
Stated Interest Rate	10.00%
Conversion Terms	Variable at $9.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		27,500
Convertible Note4 [Member]
Issue Date	--08-20
Maturity Date	--08-20
Stated Interest Rate	8.00%
Conversion Terms	Variable at $9.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		20,000
Convertible Note5 [Member]
Issue Date	--10-15
Maturity Date	--10-15
Stated Interest Rate	8.00%
Conversion Terms	Variable at $12.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		340,000
Convertible Note6 [Member]
Issue Date	--11-20
Maturity Date	--11-20
Stated Interest Rate	5.00%
Conversion Terms	Variable at $9.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		10,748
Convertible Note7 [Member]
Issue Date	--12-18
Maturity Date	--12-14
Stated Interest Rate	9.00%
Conversion Terms	Fixed at $10.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		50,000
Convertible Note8 [Member]
Issue Date	--01-05
Maturity Date	--05-31
Stated Interest Rate
Conversion Terms	Fixed at $8.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		452,729
Convertible Note9 [Member]
Issue Date	--01-31
Maturity Date	--05-31
Stated Interest Rate
Conversion Terms	Fixed at $4.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		24,135
Convertible Note10 [Member]
Issue Date	--02-27
Maturity Date	--02-27
Stated Interest Rate	5.00%
Conversion Terms	Variable at $9.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		58,500
Convertible Note11 [Member]
Issue Date	--04-02
Maturity Date	--06-02
Stated Interest Rate	8.00%
Conversion Terms	Fixed at $7.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		80,967
Convertible Note12 [Member]
Issue Date	--04-18
Maturity Date	--12-18
Stated Interest Rate	8.00%
Conversion Terms	Fixed at $7.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		31,688
Convertible Note13 [Member]
Issue Date	--05-02
Maturity Date	--05-31
Stated Interest Rate	10.00%
Conversion Terms	Variable at $3.44
Principal Balance December 31, 2014
Principal Balance December 31,2013		50,000
Convertible Note14 [Member]
Issue Date	--05-05
Maturity Date	--07-05
Stated Interest Rate	8.00%
Conversion Terms	Fixed at $7.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		45,000
Convertible Note15 [Member]
Issue Date	--05-14
Maturity Date	--05-14
Stated Interest Rate	8.00%
Conversion Terms	Fixed at $6.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		126,000
Convertible Note16 [Member]
Issue Date	--06-27
Maturity Date	--06-27
Stated Interest Rate	5.00%
Conversion Terms	Variable at $9.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		37,620
Convertible Note17 [Member]
Issue Date	--06-19
Maturity Date	--06-19
Stated Interest Rate	10.00%
Conversion Terms	Variable at $9.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		32,000
Convertible Note18 [Member]
Issue Date	--07-12
Maturity Date	--07-12
Stated Interest Rate	8.00%
Conversion Terms	Fixed at $3.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		96,800
Convertible Note19 [Member]
Issue Date	--10-18
Maturity Date	--04-18
Stated Interest Rate
Conversion Terms	Variable at $1.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		94,444
Convertible Notes I [Member]
Issue Date	--11-01
Maturity Date	--05-01
Stated Interest Rate
Conversion Terms	Variable at $1.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		80,000
Convertible Notes II [Member]
Issue Date	--12-19
Maturity Date	--06-19
Stated Interest Rate
Conversion Terms	Variable at $1.00
Principal Balance December 31, 2014
Principal Balance December 31,2013		$ 277,222

CONVERTIBLE NOTES PAYABLE (Details Narrative)	12 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative)	Dec. 31, 2014 USD ($) shares
Debt Disclosure [Abstract]
Convertible notes issued	$ 418,000
Debt	4,700,000
Accrued interest for shares of preferred stock	$ 500,000
Shares of common stock \| shares	1,400,000
fair value	$ 31,000,000
Loss on extinguishment associated with the note conversions	24,900,000
Extinguishment of the derivative liability - conversion option	$ 700,000

LOANS PAYABLE (Details Narrative) - USD ($)	12 Months Ended
LOANS PAYABLE (Details Narrative) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]
Unsecured loan advances amount	$ 0	$ 42,200
Investors converted	37,000
Related party converted	$ 5,200

PROMISSORY NOTES, RELATED PARTY (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Outstanding promissory notes	$ 52,942	$ 277,942
OIfficer and Director [Member]
Outstanding promissory notes	23,000
Amount of promissory notes repaid	15,000	$ 0
Preferred stock
Accrued interest	12,000
Outstanding principal	$ 210,000

DUE TO RELATED PARTIES (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
DUE TO RELATED PARTIES (Details Narrative) - USD ($)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]
Outstanding promissory note amount			$ 0	$ 369,000
Related parties note		$ 369,000	$ 369,000

CAPITAL STOCK (Details) - $ / shares	3 Months Ended	12 Months Ended
CAPITAL STOCK (Details) - $ / shares	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of Warrants
Balance, December 31, 2013	65,430	65,430	65,430
Issued
Cancelled/Forfeited
Balance, December 31, 2014		65,430	65,430
Weighted Average Exercise Price
Balance, December 31, 2013		$ 18.00	$ 18.00
Issued
Cancelled/Forfeited
Balance, December 31, 2014		$ 18.00	$ 18.00
Weighted Average Remaining Life
Balance, December 31, 2013			6 years 18 days
Issued		0 years	0 years
Cancelled/Forfeited		0 years	0 years
Balance, December 31, 2014		4 years 15 days	5 years 15 days
SharePurchaseWarrants[Member]
Number of Warrants
Balance, December 31, 2013	2,659,417	149,452
Issued	62,090,975	2,546,132
Exercised
Extinguished or expired	(7,500)	(36,167)
Balance, December 31, 2014	64,742,892	2,659,417	149,452
Weighted Average Exercise Price
Balance, December 31, 2013		$ 25.85
Issued	$ 1.03	1.30
Exercised
Extinguished or expired	50.00	40.00
Balance, December 31, 2014	$ 1.01	$ 1.83
Weighted Average Remaining Life
Balance, December 31, 2013	4 years 1 month 24 days	2 years 9 months 4 days
Issued	3 years 11 months 16 days	4 years 2 months 23 days
Exercised		0 years
Extinguished or expired		0 years
Balance, December 31, 2014	3 years 11 months 12 days	4 years 1 month 24 days

CAPITAL STOCK (Details 1)	12 Months Ended
CAPITAL STOCK (Details 1)	Dec. 31, 2014 $ / shares shares
Number of Shares
Unvested, December 31, 2013 \| shares	1,111
Granted \| shares
Vested \| shares	(833)
Cancelled \| shares
Unvested, December 31, 2014 \| shares	278
Weighted Average Grant-Date Fair Value
Unvested, December 31, 2013 \| $ / shares	$ 18.00
Granted \| $ / shares
Vested \| $ / shares	18.00
Cancelled \| $ / shares
Unvested, December 31, 2014 \| $ / shares	$ 18.00

CAPITAL STOCK (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
CAPITAL STOCK (Details Narrative) - USD ($)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Preferred stock			1,250,000
Shares of common stock			811,000
Preferred stock value	$ 0.001		$ 0.001	$ 0.001
Accrued interest		$ 476,000	$ 525,000
Stock based consulting and management fees			15,000	$ 132,093
Incremental fair value			$ 14,000
Number of outstanding shares of common stock			100
Common stock authorized first			150,000,000
Common stock authorized	500,000,000		500,000,000	500,000,000
Share issued			100,000
Intrinsic value of the vested options			$ 0	$ 0
Expensed portion of value of the granted and vested options			15,000	$ 0
Fair value of share purchase warrants			14,000
Private Placement [Member]
Received subscription proceeds1			1,836,000
Received subscription proceeds			$ 265,000
Preferred stock			265,000
Shares of common stock			1,886,792
Preferred stock value			$ 2.50
Fair value			$ 5,250
Number of outstanding shares of common stock			5,250
Share issued			94,340
Excercise price			$ 1.06
Contractual term			5 years
Risk free interest rate			1.66%
Dividend yield			0.00%
Annual volatility			150.30%
Fair value of share purchase warrants			$ 111,000
Excercise price of warrant			$ 1.17
Exercise price of placement shares			$ 1.325
Series B Preferred Stock [Member]
Preferred stock			1,500,000
Preferred stock value	$ 0.001		$ 0.001	$ 0.001
Series A Preferred Stock [Member]
Preferred stock value	$ 0.001		$ 0.001	$ 0.001
Common Stock [Member]
Shares of common stock			100,000
Fair value			$ 954,000
SharePurchaseWarrants[Member]
Fair value			$ 105,000
Share issued			100,000
Excercise price			$ 1.15
Contractual term			5 years
Risk free interest rate			1.63%
Dividend yield			0.00%
Annual volatility			150.30%
Fair value of share purchase warrants			$ 303,000
Minimum [Member]
Excercise price			$ 1.06
Maximum [Member]
Excercise price			$ 4.00
March 2014 [Member] \| SharePurchaseWarrants[Member]
Share issued			100,000
Excercise price			$ 4.00
Contractual term			4 years
Risk free interest rate			1.40%
Dividend yield			0.00%
Annual volatility			156.60%

INCOME TAXES (Details) - USD ($)	12 Months Ended
INCOME TAXES (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Federal:
Current
Deferred	(1,265,000)	(1,321,000)
State:
Current
Deferred
Deferred Income Tax Expense (Benefit)	(1,265,000)	(1,321,000)
Change in valuation allowance	1,265,000	1,321,000
Income tax provision (benefit)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforwards	$ 10,433,000	$ 9,174,000
Stock-based compensation	1,871,000	1,866,000
Technology licensing fee	167,000	167,000
Total deferred tax assets	12,471,000	11,207,000
Valuation allowance	(12,471,000)	(11,207,000)
Deferred tax assets, net of valuation allowance

INCOME TAXES (Details 2) - USD ($)	12 Months Ended
INCOME TAXES (Details 2) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Details
U.S. federal statutory rate	$ (10,449,000)	$ (1,881,000)
Permanent differences- Non-cash loss on extinguishment of debt	9,122,000	893,000
Permanent differences-Other permanent differences	62,000	(334,000)
Change in valuation allowance	1,265,000	1,321,000
Income tax provision (benefit)

INCOME TAXES (Details Narrative) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Details
Unrecognized tax benefits	$ 0	$ 0
Accrued amount for payment of interest and penalties	0	0
Federal net operating loss carryforwards	$ 30,686,428	$ 26,982,085

CONTINGENCIES AND COMMITMENTS (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Number of post-consolidated shares of common stock	112,000	112,000
Claim for alleged damages	$ 362,000	$ 362,000
Bond payment	100,000	100,000
Amount paid by consultant	$ 196,204	$ 196,204
Interest paid by consultant	9.00%	9.00%
Unpaid legal fees	$ 210,255	$ 210,255
Award amount	196,204	196,204
Judgment award amount	$ 51,000	$ 51,000

SUBSEQUENT EVENTS (Details Narrative)	12 Months Ended
SUBSEQUENT EVENTS (Details Narrative)	Dec. 31, 2014 USD ($) $ / shares shares
March 9, 2015 [Member]
Units of shares purchased by investors \| shares	5,000,000
Purchase price per share	$ 0.20
Total purchase price \| $	$ 950,000
Net of finders’ fee and offering expenses \| $	$ 50,000
Percentage of number of shares of common stock sold in the offering to the placement agents	2.50%
January 12, 2015 [Member]
Units of shares purchased by investors \| shares	7,320,000
Purchase price per share	$ 0.20
Total purchase price \| $	$ 1,250,000
Net of finders’ fee and offering expenses \| $	$ 214,000
Percentage of number of shares of common stock sold in the offering to the placement agents	5.00%
January 12, 2015 [Member] \| Series A Warrant [Member]
Exercise price of the warrants	$ 1.50
Maturity term of warrants	5 years
January 12, 2015 [Member] \| Series B Warrant [Member]
Exercise price of the warrants	$ 0.40
Maturity term of warrants	6 months
January 12, 2015 [Member] \| Series C Warrant [Member]
Exercise price of the warrants	$ 1.00
Maturity term of warrants	5 years
January 12, 2015 [Member] \| Series D Warrant [Member]
Exercise price of the warrants	$ 0.75
Maturity term of warrants	5 years
January 12, 2015 [Member] \| Series E Warrant [Member]
Exercise price of the warrants	$ 1.25
Maturity term of warrants	5 years

Label	Element	Value
SharePurchaseWarrants[Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	$ 1.83